[Affection of target organs in hypertensive patients with and without metabolic syndrome]

Terapevticheskii Arkhiv
|August 12, 2009
PubMed

Insights

Metabolic syndrome accelerates target organ damage in patients with arterial hypertension (AH). This study found that metabolic syndrome leads to earlier and more severe heart, kidney, and vessel damage in AH patients.

Area of Science:

  • Cardiology
  • Nephrology
  • Vascular Medicine

Background:

  • Arterial hypertension (AH) is a significant risk factor for cardiovascular and renal diseases.
  • Metabolic syndrome (MS) is increasingly recognized as a contributor to cardiovascular complications.
  • Understanding the interplay between AH, MS, and target organ damage is crucial for effective management.

Purpose of the Study:

  • To investigate the impact of metabolic syndrome (MS) on target organ damage in patients with arterial hypertension (AH).
  • To compare the severity of cardiac, renal, and vascular damage in hypertensive patients with and without MS.
  • To assess the correlation between metabolic abnormalities and specific markers of organ damage.

Main Methods:

  • Enrolled 303 patients with AH (grades 1-3), divided into groups with and without MS.
  • Assessed lipid profile, blood glucose, glomerular filtration rate, and microalbuminuria (MAU).
  • Utilized 24-hour blood pressure monitoring, echocardiography, and carotid artery Doppler ultrasonography.

Main Results:

  • Early AH showed diastolic left ventricular (LV) dysfunction, reduced glomerular filtration rate, and MAU.
  • AH grade 2 was associated with LV remodeling; grade 3 showed increased LV myocardial mass (LVMM) and intima-media thickness (TIM).
  • Strong correlations were observed between diastolic dysfunction, MAU, LVMM, and TIM.

Conclusions:

  • Metabolic syndrome exacerbates target organ damage in arterial hypertension.
  • Hypertensive patients with MS experience earlier and more severe cardiac, renal, and vascular alterations.
  • Early detection and management of MS are vital in AH patients to prevent progressive organ damage.
Abstract

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Disorders of the Autonomic Nervous System01:18

Disorders of the Autonomic Nervous System

The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's phenomenon, is a...